Editorial: Sharpening the focus in mood disorders: From disease models to individualized measurement-based care

Annals of Clinical Psychiatry

Volumn 19, Issue 4, 2007, Pages 213-214

  McIntyre, Roger S ^a   Konarski, Jakub Z ^a   Gupta, Sanjay ^b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Olean General Hospital   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; MOOD STABILIZER;

BIPOLAR DISORDER; COGNITIVE THERAPY; DEPRESSION; DISABILITY; EDITORIAL; GENDER; HUMAN; MOOD DISORDER; MORTALITY; NEUROIMAGING; PRIORITY JOURNAL; SEASONAL AFFECTIVE DISORDER; SEASONAL VARIATION;

DEPRESSIVE DISORDER; DIAGNOSIS, DIFFERENTIAL; DISABILITY EVALUATION; HUMANS; MOOD DISORDERS; PATIENT CARE; RECURRENCE;

EID: 36749036680     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230701653211     Document Type: Editorial

References (14)

1. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993 November; 54:405-418
2. McIntyre RS, Konarski JZ. Bipolar disorder: A national health concern. CNS Spectr 2004 December; 9(Suppl 12):6-15
3. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997 May 17; 349(9063):1436-1442
4. Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg PE, Hirschfield RM, Wang PS. Considering the costs of bipolar depression. Behav Healthc 2007 January; 27:45-47
5. Simon GE, Revicki D, Heiligenstein J, Grothaus L, VonKorff M, Katon WJ, Hylan TR. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000 May; 22:153-162
6. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ; STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006 March 23; 354:1243-1252
7. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME. Predictors of recurrence in bipolar disorder: Primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am J Psychiatry 2006 February; 163:217-224
8. Mathew SJ, Keegan K, Smith L. Glutamate modulators as novel interventions for mood disorders. Rev Bras Psiquiatr 2005 September; 27:243-248
9. Sheline YI, Wang PW, Gado MH, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 1996 April 30; 93:3908-3913
10. MacQueen GM, Campbell S, McEwen BS, MacDonald K, Amano S, Joffe RT, Nahmias C, Young LT. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci U S A 2003 February 4; 100:1387-1392
11. Sheline YI, Sanghavi M, Mintun MA, Grado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999 June 15; 19:5034-5043
12. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003 August 1; 54:317-329
13. McEwen BS. Mood disorders and allostatic load. Biol Psychiatry 2003 August 1; 54:200-207
14. Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 2003 November; 1003:250-272